This study is to see how well MSP-2020 attaches to specific targets in the brain called serotonin type 2A receptors (5-HT2AR). This study will also look at how much of the study drug (and its metabolite) is in the blood and how long the study drug stays in the blood, as well as the safety of MSP 2020.
Able to stay in the CRU for up to 4 days.
Body mass index (BMI) between 18.0 to 32.0 kg/m2 (inclusive).
In good health as determined by: a. Medical history; b. Physical and neurological examination; c. Concomitant medications; d. ECG; e. Screening echocardiogram; f. Serum chemistry, urinalysis, haematology, coagulation, and serology (HIV screen, HBsAg, and anti-HCV) tests.
In first-degree relatives, a history of any schizophrenia-spectrum disorder, psychotic disorder, or bipolar and related disorders.
History of allergy to tracer [11C]CIMBI-36.
MRI incompatibility due to implants including but not limited to pacemaker, artificial joints, or non-removable body piercings, and/or other contraindications for MRI such as claustrophobia, metal objects/fragments, or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals (eg, welding), or have motor problems that prevent the participant from lying still for the MRI.
Pathological MRI findings that would preclude from trial participation.
Sequential
MSP-2020
Drugcapsule
Percent Change in Specific Binding of [11C]CIMBI-36 from Baseline and EC50 Using Cortical Regions [11C]CIMBI-36 BPND
PK Plasma Concentration of MSP-2020 and its Metabolite
Maximum (peak) Plasma Concentration of MSP-2020 and its Metabolite
Time to Maximum (peak) Plasma Concentration of MSP-2020 and its Metabolite
Change from baseline in relevant scales
Concentration of the metabolite at which 50% of the 5-HT2A receptors are occupied, as measured by PET imaging
Number of Participants With Adverse Events (AEs)
Number of Participants With Potentially Clinically Significant Changes in Vital Signs
Click on the lead sponsor to view all of their trials.
